Immunotherapy with BCG-CWS (Cell-Wall Skeleton) in Patients with Primary Lung Cancer

DOI PubMed
  • Takano T.
    The 2nd Department of Internal Medicine, Nagoya City University Medical School
  • Morishita M.
    The 2nd Department of Internal Medicine, Nagoya City University Medical School
  • Yamamoto M.
    The 2nd Department of Internal Medicine, Nagoya City University Medical School
  • Yamagata K.
    The 2nd Department of Internal Medicine, Nagoya City University Medical School
  • Takada K.
    The 2nd Department of Internal Medicine, Nagoya City University Medical School

Bibliographic Information

Other Title
  • 肺癌患者に対するBCG-CWSによる免疫療法の効果

Search this article

Description

BCG-CWS was administered in 30 patients with primary lung cancer, and in most cases this was in conjunction with other therapeutic procedures such as irradiation, chemotherapy and/or surgery.<br>Oil-attached BCG-CWS was prepared by homogenizing 4mg of BCG-CWS, two drops of mineral oil and 2ml of 0.2% Tween 80 saline.<br>Two hundred μg of BCG-CWS was injected intradermally every week. In patients with carcinomatous pleuritis, 400μg of BCG-CWS was injected into the pleural cavity every week.<br>Prolonged survival periods in advanced lung cancer cases treated with BCG-CWS was observed in comparison with historical controls. Most of the patients showed increased PPD skin reaction and increased in vitro PHA response after BCG-CWS administration.<br>As adverse reactions, minimal skin ulceration was observed in 37% of the patients, and fever in 57% after repeated intradermal injection of BCG-CWS, none of which necessitated the interruption of immunotherapy. No serious side effects, however, have been observed during the BCG-CWS treatment.

Journal

Details 詳細情報について

Report a problem

Back to top